Education
About Us
Working with TipRanks
Follow Us
Cns Pharmaceuticals, Inc. (CNSP)
:CNSP
CNSP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.93 - $221.40
Previous CloseN/A
Volume19.26M
Average Volume (3M)76.58K
Market Cap
$5.11M
Enterprise Value-$8.34M
Total Cash (Recent Filing)$12.13M
Total Debt (Recent Filing)$121.77K
Price to Earnings (P/E)―
Beta2.34
Next Earnings
Nov 12, 2025EPS Estimate
-6.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.42
Shares Outstanding574,580
10 Day Avg. Volume77,406
30 Day Avg. Volume76,577
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-1.63
Enterprise Value/Revenue-2.66K
Enterprise Value/Gross Profit6.04K
Enterprise Value/Ebitda0.54
Forecast
1Y Price Target
$20.00Price Target Upside124.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsTPI-287 demonstrated an overall response rate of 60% in a Phase 1 trial for rGBM, with a 96% disease control rate, indicating promising efficacy.
Drug DevelopmentCNS Pharmaceuticals is upgrading shares to Buy due to the pivot to its oncology asset TPI-287, which is in development for recurrent glioblastoma (rGBM).
Bears Say
Analyst DowngradeIt is unclear what the path forward is for Berubicin, and given that Berubicin was the main driver of our thesis, analysts are removing it from their model and downgrading CNSP shares to Hold, from Buy.
Trial FailureCNS Pharmaceuticals shares are at an all-time low due to the Berubicin trial missing its primary endpoint in March.
CNS Pharmaceuticals News
CNSP FAQ
What was Cns Pharmaceuticals, Inc.’s price range in the past 12 months?
Cns Pharmaceuticals, Inc. lowest stock price was $4.93 and its highest was $221.40 in the past 12 months.
What is Cns Pharmaceuticals, Inc.’s market cap?
Cns Pharmaceuticals, Inc.’s market cap is $5.11M.
When is Cns Pharmaceuticals, Inc.’s upcoming earnings report date?
Cns Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 12, 2025 which is in 42 days.
How were Cns Pharmaceuticals, Inc.’s earnings last quarter?
Cns Pharmaceuticals, Inc. released its earnings results on Aug 14, 2025. The company reported -$6.42 earnings per share for the quarter, beating the consensus estimate of -$9.6 by $3.18.
Is Cns Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Cns Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Cns Pharmaceuticals, Inc. pay dividends?
Cns Pharmaceuticals, Inc. does not currently pay dividends.
What is Cns Pharmaceuticals, Inc.’s EPS estimate?
Cns Pharmaceuticals, Inc.’s EPS estimate is -6.63.
How many shares outstanding does Cns Pharmaceuticals, Inc. have?
Cns Pharmaceuticals, Inc. has 574,580 shares outstanding.
What happened to Cns Pharmaceuticals, Inc.’s price movement after its last earnings report?
Cns Pharmaceuticals, Inc. reported an EPS of -$6.42 in its last earnings report, beating expectations of -$9.6. Following the earnings report the stock price went down -11.193%.
Which hedge fund is a major shareholder of Cns Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in CNSP
CNS Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (124.97% Upside)
$20.00 (124.97% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.48%
12-Months-Change
Fundamentals
Return on Equity
-350.08%
Trailing 12-Months
Asset Growth
487.54%
Trailing 12-Months
Company Description
Cns Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
CNSP Stock 12 Month Forecast
Average Price Target
$20.00
▲(124.97% Upside)
Technical Analysis
Qualigen Therapeutics
―
Aptevo Therapeutics
―
Entero Therapeutics
―
Nucana
―
NLS Pharmaceutics
―
Ownership Overview
10.50% Insiders
<0.01% Mutual Funds
0.21% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---